These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2663161)

  • 1. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsiella pneumoniae.
    Shungu DL; Ponticas S; Gill CJ
    Clin Ther; 1989; 11(3):315-8. PubMed ID: 2663161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activities of antibacterial agents against clinical isolates of Escherichia coli and Klebsiella species from intensive care units.
    Gill CJ; Ponticas S; Shungu DL; Guerriero S
    Clin Ther; 1991; 13(1):25-37. PubMed ID: 2029725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.
    Shahid M; Malik A; Akram M; Agrawal LM; Khan AU; Agrawal M
    Int J Infect Dis; 2008 May; 12(3):256-64. PubMed ID: 17981482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Kacmaz B; Sultan N
    Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
    Wang FD; Lin ML; Lee WS; Liu CY
    Int J Antimicrob Agents; 2004 Jun; 23(6):590-5. PubMed ID: 15194130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of meropenem compared with imipenem, metronidazole, ampicillin, and ampicillin/sulbactam against anaerobes.
    Schumacher U; Manncke B; Gerbracht K; Werner H
    Arzneimittelforschung; 1994 Jul; 44(7):859-62. PubMed ID: 7945523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Distribution and drug-resistance of 3 500 gram-negative bacteria in Guangzhou].
    Xiao QZ; Su DH; Jiang JH; Zhong NS
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Feb; 25(2):132-8. PubMed ID: 15698988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
    Sullivan MC; Nightingale CH; Quintiliani R; Sweeney KR
    Pharmacotherapy; 1995; 15(4):479-86. PubMed ID: 7479201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activity of 9 beta-lactam antibiotics combined with clavulanic acid or sulbactam against the strains of broad-spectrum beta-lactamase (CTX-1) producing Enterobacteriaceae isolated at the Henri Mondor Hospital].
    Legrand P; Soussy CJ; Orsoni A; Brickley X; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):425-9. PubMed ID: 3043338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China].
    Chen MJ; Wang H;
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
    Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
    Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sanfetrinem, the member of trinems--in vitro activity against Klebsiella pneumoniae producing ESBL].
    Wieczorek P; Sacha PT; Leszczyńska K; Jakoniuk P; Zalewska M
    Med Dosw Mikrobiol; 2006; 58(1):27-32. PubMed ID: 16871970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of phenotypic screening methods for detecting plasmid-mediated AmpC beta-lactamases-producing isolates of Escherichia coli and Klebsiella pneumoniae.
    Lee K; Hong SG; Park YJ; Lee HS; Song W; Jeong J; Yong D; Chong Y
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):319-23. PubMed ID: 16269222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.
    Liao CH; Sheng WH; Wang JT; Sun HY; Wang HK; Hsueh PR; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2006 Feb; 39(1):59-66. PubMed ID: 16440125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province.
    Yu Y; Zhou W; Chen Y; Ding Y; Ma Y
    Chin Med J (Engl); 2002 Oct; 115(10):1479-82. PubMed ID: 12490091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the evolution of imipenem susceptibility among Klebsiella pneumoniae and Escherichia coli isolates during a 6-year period in a tertiary care hospital.
    Papaparaskevas J; Pantazatou A; Stefanou I; Mela V; Galatidis N; Avlamis A
    Int J Antimicrob Agents; 2007 Feb; 29(2):197-200. PubMed ID: 17207610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended spectrum b lactamases (ESBL) in clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    Duttaroy B; Mehta S
    Indian J Pathol Microbiol; 2005 Jan; 48(1):45-8. PubMed ID: 16758790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility trends of Bacteroides fragilis group isolates from Buenos Aires, Argentina.
    Fernández Canigia L; Castello L; Di Martino A; Greco G; Legaria MC; Litterio M; Predari SC; Rollet R; Rossetti A; Carloni G; Sarchi MI; Bianchini H
    Rev Argent Microbiol; 2007; 39(3):156-60. PubMed ID: 17987852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.